Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)

NCT02529930 is registered in ClinicalTrials.gov with Nykode Therapeutics ASA as lead sponsor.

NCT NCT02529930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02529930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)
Lead sponsor
Nykode Therapeutics ASA
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2015
Completion date
January 31, 2019
Enrollment
34 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

high grade cervical intraepithelial neoplasia